Screening beyond conventional serological markers for hepatitis B and C viruses in cirrhosis: an entity overlooked
DOI:
https://doi.org/10.18203/2320-6012.ijrms20204261Keywords:
Cirrhosis, Non-alcoholic Steatohepatitis, Occult Hepatitis B, Seronegative Hepatitis CAbstract
We aimed to emphasise the role of screening beyond conventional serological markers (HBsAg and Anti HCV antibodies for chronic viral hepatitis B and C respectively) in patients with cirrhosis. Patients with cirrhosis of liver are often labelled as having cryptogenic cirrhosis (CC), if no etiology is found. In chronic viral hepatitis B and C (CHB and CHC) induced cirrhosis, HBsAg and Anti HCV antibodies respectively are usually done to rule out the viral infections however their absence have been documented in subset of patients having these infections. In this regard, we hereby present a case labelled as CC and developed HCC; later on, further evaluation turned out to be having both CHB and CHC. A 51-year-old male with diabetes presented with index episode of hemetemesis. On further evaluation he was diagnosed to have cirrhosis of liver. No etiology was found and he was labeled as cirrhosis secondary to Non-alcoholic steatohepatitis (NASH)/cryptogenic cirrhosis. Later on, he developed hepatocellular carcinoma (HCC). We evaluated the patient with HBV DNA and HCV RNA levels keeping possibility of occult hepatitis B (OBI)/ seronegative hepatitis C infection despite HBsAg and Anti HCV antibodies being negative. Both levels were found to be raised and we attributed cirrhosis to dual hit by CHB and CHC. Patient was managed with antiviral drugs successfully with no recurrence of HCC and control of blood sugar levels. We hereby stress that screening beyond the HBsAg and Anti HCV antibodies should be done in all cases of liver cirrhosis in which etiology is not found on initial screening.
Metrics
References
Mukherjee PS, Vishnubhatla S, Amarapurkar DN, Das K, Sood A, Chawla YK, et al. Etiology and mode of presentation of chronic liver diseases in India: A multi centric study. PloS one. 2017; 12(10):e0187033.
Schuppan D, Afdhal NH. Liver Cirrhosis. Lan. 2008;371(9615): 838-51.
Clark JM, Diehl AM. Nonalcoholic fatty liver disease: An under recognized cause of cryptogenic cirrhosis. J Ame Med Asso. 2003;289:3000-4.
Kumar A, Acharya SK, Singh SP, Saraswat VA, Arora A, Duseja A, et al. The Indian National Association for Study of the Liver (INASL) consensus on prevention, diagnosis and management of hepatocellular carcinoma in India: the Puri recommendations. J Clin Exp Hepato. 2014;4:S3-26.
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Circulation. 2002;106:3143-421.
NCD Risk Factor Collaboration (NCD-RisC). Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19.2 million participants. Lancet. 2016;387:1377-96.
Makvandi M. Update on occult hepatitis B virus infection. World J Gastro. 2016 Oct 21;-22(39):8720-34.
Puri P, Saraswat VA, Dhiman RK, Anand AC, Acharya SK, Singh SP, et al. Indian National Association for Study of the Liver (INASL) guidance for antiviral therapy against HCV infection: update 2016. J Clin Exp Hepato. 2016;-6(2):119-45.
Arora A, Singh SP, Kumar A, Saraswat VA, Aggarwal R, Bangar M,et al. INASL position statements on prevention, diagnosis and management of hepatitis B virus infection in India: the Andaman statements. J Clin Exp Hepato. 2018;8(1):58-80.
Mokdad AA, Lopez AD, Shahraz S, Lozano R, Mokdad AH, Stanaway J et al. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. BMC Med 2014;12:145.
Aggarwal R. Hepatitis C: A success story in the making. Int J Adv Med Health Res. 2019;6:1-2.
Duseja A, Singh SP, Saraswat VA, Acharya SK, Chawla YK, Chowdhury S, et al. Non-alcoholic fatty liver disease and metabolic syndrome—position paper of the Indian National Association for the Study of the Liver, Endocrine Society of India, Indian College of Cardiology and Indian Society of Gastroenterology. J Clin Exp Hepato. 2015;5(1):51-68.
Duseja A, Chawla Y. Nonalcoholic fatty liver disease in India–how much? How soon? Trop Gastro. 2005;26:1-3.
Duseja A, Sharma B, Kumar A, et al. Nonalcoholic fatty liver in a developing country is responsible for significant liver disease. Hepato. 2010;52:2248-9.
Nayak NC, Vasdev N, Saigal S, Soin AS. End-stage nonalcoholic fatty liver disease: evaluation of pathomorphologic features and relationship to cryptogenic cirrhosis from study of explant livers in a living donor liver transplant program. Hum Pathol. 2010;41:425–30.
1Duseja A. Nonalcoholic fatty liver disease in India - is it different? Trop Gastroenterol. 2006;27:142–6.
Younossi ZM, Henry L, Bush H, Mishra A. Clinical and economic burden of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Clini liver dise. 2018;22(1):1-10.
Kaźmierczak J, Pawełczyk A, Cortes KC, Radkowski M. Seronegative hepatitis C virus infection. Archi immunolo therapiae experi. 2014;62(2):145-51.
Schmidt WN, Wu P, Cederna J, Mitros FA, LaBrecque DR, Stapleton JT. Surreptitious hepatitis C virus (HCV) infection detected in the majority of patients with cryptogenic chronic hepatitis and negative HCV antibody tests. J Infe Dise. 1997;176(1):27-33.
Tugwell BD, Patel PR, Williams IT, Hedberg K, Chai F, Nainan OV, et al. Transmission of hepatitis C virus to several organ and tissue recipients from an antibody-negative donor. Anna Internal Med. 2005;143(9):648-54.
Serfaty L. Metabolic manifestations of hepatitis C virus: diabetes mellitus, dyslipidemia. Clin liver dise. 2017;21(3):475-86.
Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepato. 2008;49(4):652-7.
Hou J, Wang Z, Cheng J, Lin Y, Lau GK, Sun J, et al. Prevalence of naturally occurring surface gene variants of hepatitis B virus in nonimmunized surface antigennegative Chinese carriers. Hepato. 2001;34:1027-34.
Mrani S, Chemin I, Menouar K, Guillaud O, Pradat P, Borghi G, et al. Occult HBV infection may represent a major risk factor of nonresponse to antiviral therapy of chronic hepatitis C. J Med Virol. 2007;79:1075-81.
Agarwal N, Naik S, Aggarwal R, Singh H, Somani SK, Kini D, Pandey R, Choudhuri G, Saraswat VA, Naik SR. Occult hepatitis B virus infection as a cause of cirrhosis of liver in a region with intermediate endemicity. Indian J Gastro. 2003; 22:127-31.
Lok ASF, Negro F. Hepatitis B and D. In: Schiff ER, Maddrey WC, Reddy KR. Schiff’s Disease of the Liver. 11th ed. Oxford: Wiley Blackwell; 2012;537-81.
Marrero JA, Lok AS. Occult hepatitis B virus infection in patients with hepatocellular carcinoma: innocent bystander, cofactor, or culprit? Gastroent. 2004;126:347–50.
Schmeltzer P, Sherman KE. Occult hepatitis B: clinical implications and treatment decisions. Digestive diseases and sciences. 2010;55(12):3328-35.
Alnaqy A, Al-Harthy S, Kaminski G, Al-Dhahry S. Detection of serum antibodies to hepatitis C virus in ‘false-seronegative’blood donors in Oman. Medical Principles and Practice. 2006;15(2):111-3.
Pawlotsky JM, Bastie A, Pellet C, Remire J, Darthuy F, Wolfe L, et al. Significance of indeterminate third-generation hepatitis C virus recombinant immunoblot assay. J Clinical microbio. 1996;34(1):80-3.
Larouche A, Gaëtan G, El-Bilali N, Quesnel-Vallières M, Martin SR, Alvarez F, et al. Seronegative hepatitis C virus infection in a child infected via mother-to-child transmission. J Clinical microbio. 2012;50(7):2515-9.
Downloads
Published
How to Cite
Issue
Section
